Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases.
Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases.
The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19.
It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease.
Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD.
The company was incorporated in 2006 and is headquartered in Paris, France.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 18, 23 | 0.00 Decreased by N/A% | - |
| Mar 31, 23 | 0.00 Decreased by N/A% | - |
| Oct 31, 22 | 0.00 Decreased by N/A% | - |
| May 26, 22 | 0.00 Increased by +100.00% | - |
| Feb 26, 22 | 0.00 Increased by +100.00% | - |
| Dec 1, 21 | 0.00 Increased by +100.00% | - |
| Sep 17, 21 | 0.00 Increased by +100.00% | - |
| Jun 30, 21 | -0.07 Increased by +65.75% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | N/A Decreased by N/A% | -9.26 M Decreased by N/A% | - - |
| Jun 30, 23 | N/A Decreased by N/A% | -7.76 M Increased by +37.38% | - - |
| Mar 31, 23 | N/A Decreased by N/A% | -11.82 M Increased by +34.35% | - - |
| Dec 31, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Sep 30, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Jun 30, 22 | N/A Decreased by N/A% | -12.40 M Increased by +6.39% | - - |
| Mar 31, 22 | N/A Decreased by N/A% | -18.00 M Decreased by N/A% | - - |
| Dec 31, 21 | N/A Decreased by N/A% | N/A Increased by +100.00% | - - |